JEFFREY A. COHEN
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- Independence, OH
- NPI
- 1104867118
- Received
- $125,214 in 83 records, 2019 to 2025 ($88,200 general, $37,014 research)
- As principal investigator
- $3,007,176 of research payments to others in 50 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 12 | $18,755 |
| 2025 | Research payment | 1 | $2,860 |
| 2024 | General payment | 3 | $3,755 |
| 2023 | General payment | 7 | $9,916 |
| 2023 | Research payment | 2 | $4,577 |
| 2022 | General payment | 3 | $6,124 |
| 2022 | Research payment | 6 | $5,225 |
| 2021 | General payment | 10 | $12,868 |
| 2021 | Research payment | 3 | $7,722 |
| 2020 | General payment | 5 | $6,480 |
| 2020 | Research payment | 5 | $5,667 |
| 2019 | General payment | 17 | $30,299 |
| 2019 | Research payment | 9 | $10,960 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 23 | $29,218 | 2019–2025 |
| Mylan Inc. | 10 | $18,037 | 2019–2025 |
| Celgene Corporation | 8 | $16,597 | 2019–2025 |
| Adamas Pharmaceuticals, Inc. | 2 | $14,099 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 5 | $10,855 | 2023–2025 |
| Novartis Pharma AG | 4 | $7,626 | 2019–2023 |
| Janssen Global Services, LLC | 7 | $5,890 | 2020–2021 |
| F. Hoffmann-La Roche AG | 6 | $4,148 | 2019–2020 |
| Legend Biotech USA Inc. | 2 | $3,775 | 2025 |
| EMD Serono, Inc. | 3 | $3,698 | 2022–2025 |
| Merck KGaA | 1 | $2,650 | 2022 |
| GlaxoSmithKline, LLC. | 2 | $1,892 | 2021 |
| AstraZeneca Pharmaceuticals LP | 1 | $1,879 | 2025 |
| Hexal AG | 1 | $1,300 | 2023 |
| Biogen, Inc. | 1 | $1,226 | 2023 |
| Shionogi Inc | 1 | $1,220 | 2025 |
| Genentech, Inc. | 1 | $900 | 2020 |
| TG Therapeutics, Inc. | 1 | $127 | 2025 |
| PFIZER INC. | 3 | $51 | 2023–2024 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 32 | $57,290 |
| Research payment | 26 | $37,014 |
| Travel and Lodging | 7 | $16,890 |
| Honoraria | 1 | $7,049 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 6 | $6,471 |
| Food and Beverage | 10 | $421 |
| Gift | 1 | $77 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-06 | AstraZeneca Pharmaceuticals LP | $1,879 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Legend Biotech USA Inc. | $3,020 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | Legend Biotech USA Inc. | $755 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-03 | Novartis Pharmaceuticals Corporation | $4,331 | Consulting Fee | Cash or cash equivalent | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-04 | Mylan Inc. | $2,132 | Consulting Fee | Cash or cash equivalent | TOBI PODHALER Drug, Aminoglycosides | 2025 | |
| 2025-07-18 | Shionogi Inc | $1,220 | Consulting Fee | Cash or cash equivalent | S-740792 Drug, Neurology | 2025 | |
| 2025-07-15 | E.R. Squibb & Sons, L.L.C. | $3,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-28 | E.R. Squibb & Sons, L.L.C. | $1,920 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-10 | Novartis Pharmaceuticals Corporation | $2,860 | Research payment | In-kind items and services | KESIMPTA Drug, Neurology | Research Publication/Writing Support | 2025 |
| 2025-03-04 | TG Therapeutics, Inc. | $127 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-02-26 | Celgene Corporation | $64 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-26 | Celgene Corporation | $29 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-13 | EMD Serono, Inc. | $77 | Gift | In-kind items and services | 2025 | ||
| 2024-12-17 | E.R. Squibb & Sons, L.L.C. | $1,920 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-07 | E.R. Squibb & Sons, L.L.C. | $1,815 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-06 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2024 | |
| 2023-12-22 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2023 | |
| 2023-10-24 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2023 | |
| 2023-10-05 | Biogen, Inc. | $1,226 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2023 | |
| 2023-09-07 | Hexal AG | $1,300 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | EMD Serono, Inc. | $3,360 | Consulting Fee | Cash or cash equivalent | Evobrutinib | 2023 | |
| 2023-06-13 | E.R. Squibb & Sons, L.L.C. | $2,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-13 | Celgene Corporation | $2,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-30 | Novartis Pharma AG | $2,409 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | COMB157G2302 | 2023 |
| 2023-02-15 | Novartis Pharmaceuticals Corporation | $2,168 | Research payment | In-kind items and services | KESIMPTA Drug, Neurology | COMB157G2301 | 2023 |
| 2022-12-07 | EMD Serono, Inc. | $261 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-06-02 | Novartis Pharmaceuticals Corporation | $1,770 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-06-02 | Novartis Pharmaceuticals Corporation | $983 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-06-02 | Novartis Pharmaceuticals Corporation | $983 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-02-24 | Merck KGaA | $2,650 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-09 | Mylan Inc. | $3,213 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-01-31 | Novartis Pharmaceuticals Corporation | $705 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-01-31 | Novartis Pharmaceuticals Corporation | $392 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-01-31 | Novartis Pharmaceuticals Corporation | $392 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2021-10-21 | Novartis Pharmaceuticals Corporation | $1,875 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE S | 2021 |
| 2021-08-25 | GlaxoSmithKline, LLC. | $1,432 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-17 | Novartis Pharma AG | $1,699 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | Publication support research related | 2021 |
| 2021-08-05 | GlaxoSmithKline, LLC. | $460 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-22 | Celgene Corporation | $3,100 | Consulting Fee | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-06-02 | Janssen Global Services, LLC | $620 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-04 | Novartis Pharmaceuticals Corporation | $4,148 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | 2021 |
| 2021-03-24 | Janssen Global Services, LLC | $1,860 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-24 | Janssen Global Services, LLC | $620 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-24 | Janssen Global Services, LLC | $310 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-22 | Novartis Pharmaceuticals Corporation | $1,276 | Consulting Fee | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-17 | Novartis Pharmaceuticals Corporation | $2,552 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-07 | Novartis Pharmaceuticals Corporation | $638 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2020-12-23 | Janssen Global Services, LLC | $310 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Janssen Global Services, LLC | $1,860 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-11-11 | Janssen Global Services, LLC | $310 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-30 | F. Hoffmann-La Roche AG | $676 | Research payment | In-kind items and services | Ocrevus Biological, Immunology | Safety and Tolerability of shorter infusion of Ocrevus in MS patients | 2020 |
| 2020-09-11 | Novartis Pharmaceuticals Corporation | $614 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2020 |
| 2020-08-03 | Novartis Pharma AG | $3,504 | Research payment | In-kind items and services | FTY720D_GILENYA_NEUROSCIENCE Drug, NEUROSCIENCE | Publication support research related | 2020 |
| 2020-07-15 | Novartis Pharmaceuticals Corporation | $259 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2020 |
| 2020-06-10 | Genentech, Inc. | $900 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-05-12 | Celgene Corporation | $3,100 | Consulting Fee | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-27 | Novartis Pharmaceuticals Corporation | $614 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2020 |
| 2019-12-20 | Mylan Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-10-25 | Adamas Pharmaceuticals, Inc. | $7,049 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-10-25 | Adamas Pharmaceuticals, Inc. | $7,049 | Honoraria | Cash or cash equivalent | 2019 | ||
| 2019-10-21 | Novartis Pharmaceuticals Corporation | $208 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-09-30 | F. Hoffmann-La Roche AG | $985 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-09-30 | F. Hoffmann-La Roche AG | $371 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-09-30 | Novartis Pharmaceuticals Corporation | $208 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-09-11 | Novartis Pharma AG | $13 | Food and Beverage | In-kind items and services | OMB157G_ARZERRA_HEMATOLOGY Drug, HEMATOLOGY | 2019 | |
| 2019-09-10 | Mylan Inc. | $332 | Travel and Lodging | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-10 | Mylan Inc. | $62 | Food and Beverage | In-kind items and services | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-09 | Mylan Inc. | $331 | Travel and Lodging | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-09 | Mylan Inc. | $50 | Food and Beverage | In-kind items and services | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-09 | Mylan Inc. | $31 | Travel and Lodging | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-09 | Mylan Inc. | $8 | Travel and Lodging | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-09-05 | Mylan Inc. | $8,875 | Travel and Lodging | Cash or cash equivalent | Glatiramer Acetate Drug, Central Nervous System | 2019 | |
| 2019-08-30 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | AJOVY Drug, Central Nervous System | 2019 | |
| 2019-06-30 | F. Hoffmann-La Roche AG | $1,328 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-06-30 | F. Hoffmann-La Roche AG | $422 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-05-31 | Novartis Pharmaceuticals Corporation | $670 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-05-09 | Novartis Pharmaceuticals Corporation | $670 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-03-31 | F. Hoffmann-La Roche AG | $364 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-03-01 | Celgene Corporation | $1,144 | Research payment | In-kind items and services | RPC-1063 Drug | PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC0 | 2019 |
| 2019-02-28 | Novartis Pharmaceuticals Corporation | $670 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-02-28 | Novartis Pharmaceuticals Corporation | $229 | Research payment | In-kind items and services | GILENYA Drug, NEUROSCIENCE | RESEARCH RELATED PUBLICATIONS SUPPORT | 2019 |
| 2019-01-07 | Celgene Corporation | $3,818 | Research payment | In-kind items and services | RPC-1063 Drug | A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active- | 2019 |
| 2019-01-07 | Celgene Corporation | $3,342 | Research payment | In-kind items and services | RPC-1063 Drug | A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-10-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $143 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2025-05-23 | E.R. Squibb & Sons, L.L.C. | Cleveland Clinic Hospital | $254,807 | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen | 2025 |
| 2025-04-22 | E.R. Squibb & Sons, L.L.C. | Cleveland Clinic Hospital | $19,951 | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen | 2025 |
| 2025-02-25 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $13,529 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | Cleveland Clinic Hospital | $84,208 | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $244,795 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2024-09-25 | E.R. Squibb & Sons, L.L.C. | Cleveland Clinic Hospital | $779 | CT CD19 NEX-T Phase I Esc/Exp Study for haRRMS and PPMS | 2024 |
| 2024-05-28 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $261,705 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2024 |
| 2024-01-31 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $4,790 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2024 |
| 2024-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $228,755 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2024 |
| 2023-10-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $189 | A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Re | 2023 |
| 2023-09-05 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $122,422 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $31,181 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2023 |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $570 | A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Re | 2023 |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $153,789 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2023 |
| 2022-03-24 | Biogen, Inc. | Cleveland Clinic Hospital | $56,571 | A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week | 2022 |
| 2022-01-25 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $422,549 | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT | 2022 |
| 2022-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $762 | A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE | 2022 |
| 2021-03-17 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $5,300 | A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED | 2021 |
| 2021-01-27 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $356,588 | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT | 2021 |
| 2021-01-07 | Biogen, Inc. | Cleveland Clinic Hospital | $62,344 | Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at CCF/LV | 2021 |
| 2021-01-06 | Biogen, Inc. | Cleveland Clinic Hospital | $10,903 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switchi | 2021 |
| 2021-01-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $825 | A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE | 2021 |
| 2020-12-03 | Biogen, Inc. | Cleveland Clinic Hospital | $26,719 | Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at CCF/LV | 2020 |
| 2020-11-12 | Mallinckrodt Hospital Products Inc. | Cleveland Clinic Hospital | $3,276 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2020 |
| 2020-11-09 | GENZYME CORPORATION | Cleveland Clinic Hospital | $1,196 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2020 |
| 2020-10-01 | Novartis Pharmaceuticals Corporation | THE CLEVELAND CLINIC FOUNDATION | $287 | A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE | 2020 |
| 2020-08-14 | Mallinckrodt Hospital Products Inc. | Cleveland Clinic Hospital | $4,500 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2020 |
| 2020-05-04 | Mallinckrodt Hospital Products Inc. | Cleveland Clinic Hospital | $6,266 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2020 |
| 2020-01-30 | Novartis Pharmaceuticals Corporation | Cleveland Clinic Hospital | $200,956 | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT | 2020 |
| 2020-01-21 | GENZYME CORPORATION | Cleveland Clinic Hospital | $972 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2020 |
| 2020-01-09 | Biogen, Inc. | Cleveland Clinic Hospital | $139,365 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switchi | 2020 |
| 2019-12-02 | Mallinckrodt Enterprises LLC | THE CLEVELAND CLINIC FOUNDATION | $105 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-11-25 | GENZYME CORPORATION | WAKE FOREST UNIVERSITY HEALTH SCIENCES | $798 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-11-25 | GENZYME CORPORATION | CLEVELAND CLINIC HOSPITAL | $1,201 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-10-10 | Mallinckrodt Enterprises LLC | CLEVELAND CLINIC HOSPITAL | $1,317 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-09-05 | Mallinckrodt Enterprises LLC | THE CLEVELAND CLINIC FOUNDATION | $42 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-07-22 | GENZYME CORPORATION | CLEVELAND CLINIC HOSPITAL | $15,020 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-05-30 | Mallinckrodt Enterprises LLC | CLEVELAND CLINIC HOSPITAL | $8,002 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-05-27 | GENZYME CORPORATION | CLEVELAND CLINIC HOSPITAL | $2,400 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-05-20 | Novartis Pharmaceuticals Corporation | CLEVELAND CLINIC HOSPITAL | $34,753 | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT | 2019 |
| 2019-05-08 | Novartis Pharmaceuticals Corporation | CLEVELAND CLINIC HOSPITAL | $20,285 | A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE S | 2019 |
| 2019-04-23 | Biogen, Inc. | THE CLEVELAND CLINIC FOUNDATION | $90,350 | A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Pa | 2019 |
| 2019-04-02 | Mallinckrodt Enterprises LLC | THE CLEVELAND CLINIC FOUNDATION | $137 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-02-21 | Novartis Pharmaceuticals Corporation | CLEVELAND CLINIC HOSPITAL | $90,702 | A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED | 2019 |
| 2019-02-18 | GENZYME CORPORATION | CLEVELAND CLINIC HOSPITAL | $2,532 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-02-15 | Mallinckrodt Enterprises LLC | CLEVELAND CLINIC HOSPITAL | $3,000 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-02-05 | Mallinckrodt Enterprises LLC | THE CLEVELAND CLINIC FOUNDATION | $86 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2019 |
| 2019-02-04 | Biogen, Inc. | CLEVELAND CLINIC HOSPITAL | $12,362 | A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Pa | 2019 |
| 2019-01-21 | GENZYME CORPORATION | CLEVELAND CLINIC HOSPITAL | $3,075 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Independence, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Independence, OH | County Cuyahoga County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 7,534 | 1,245,873 | 11,810,293 |
| Population, 2020 census P1 | 7,584 | 1,264,817 | 11,799,448 |
| Median age B01002 | 48.4 | 40.4 | 39.7 |
| Under 18 B01001 | 19.2% | 20.5% | 22.0% |
| 65 and over B01001 | 25.5% | 19.5% | 18.3% |
| Households B11001 | 3,121 | 554,551 | 4,863,191 |
| Foreign born B05002 | 3.1% | 7.7% | 5.2% |
| Median household income B19013 | $115,733 | $64,468 | $71,389 |
| Median family income B19113 | $126,413 | $89,252 | $92,749 |
| Per capita income B19301 | $58,711 | $42,747 | $40,552 |
| Poverty rate B17001 | 2.4% | 16.1% | 13.3% |
| Unemployment rate B23025 | 1.5% | 6.6% | 4.8% |
| Civilian labor force B23025 | 4,068 | 650,577 | 5,994,779 |
| Mean commute (minutes) B08013 | 22.6 | 23.3 | 23.4 |
| Bachelor's degree or higher B15003 | 47.4% | 36.5% | 31.5% |
| Housing units B25001 | 3,217 | 615,331 | 5,292,391 |
| Owner-occupied B25003 | 90.4% | 59.4% | 67.2% |
| Renters B25003 | 9.6% | 40.6% | 32.8% |
| Median home value B25077 | $309,900 | $195,400 | $214,800 |
| Median gross rent B25064 | $1,383 | $1,060 | $1,034 |
| White, not Hispanic B03002 | 92.4% | 56.5% | 75.8% |
| Black B03002 | 1.8% | 28.5% | 12.0% |
| Hispanic or Latino B03002 | 1.3% | 7.0% | 4.8% |
| Asian B03002 | 1.4% | 3.3% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Independence, OH.
Comments